SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]

By | 2020-10-01T15:38:30+00:00 May 22nd, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Secures $15 Million in Funding to Accelerate

[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]

By | 2020-10-01T15:38:34+00:00 May 22nd, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac The SEC also found that the participants in the activist plan were advise]

By | 2020-10-01T15:38:41+00:00 May 18th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Comments on SEC Findings Against Jiaqiang “Chiang”

[Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac The SEC also found that the participants in the activist plan were advise]

By | 2020-10-01T15:38:45+00:00 May 18th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques BEIJING, China, May 6, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a lea]

By | 2020-10-01T15:38:53+00:00 May 6th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces First Animal Study Results of Vaccine

[Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques BEIJING, China, May 6, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a lea]

By | 2020-10-01T15:38:57+00:00 May 6th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: CONTENTS

[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]

By | 2020-10-01T15:39:46+00:00 April 30th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]

By | 2020-10-01T15:39:05+00:00 April 30th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results

[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]

By | 2020-10-01T15:39:09+00:00 April 30th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]

By | 2020-10-01T15:39:43+00:00 April 30th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Skip to toolbar